REFERENCES
1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032-45.
2. Jadoul M, Rossing P. The era of combination of nephroprotective agents in CKD is there. Nephrol Dial Transplant. 2025;40:i1-2.
3. Agarwal R, Green JB, Heerspink HJL, et al. ; CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med. 2025;393:533-43.
4. Perkovic V, Jardine MJ, Neal B, et al. ; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46.
6. Herrington WG, Staplin N, Wanner C, et al. ; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27.
7. Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur. 2024;38:100847.
8. KDIGO 2026 clinical practice guideline for diabetes and chronic kidney disease (CKD) chapter 1, chapter 2, & chapter 4 update draft march 2026. Available from: https://kdigo.org/wp-content/uploads/2026/03/KDIGO-2026-Diabetes-and-CKD-Guideline-Update-Public-Review-Draft-March-2026.pdf. [Last accessed on 8 Sep 2026].
9. Bakris GL, Agarwal R, Anker SD, et al. ; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-29.
10. Pitt B, Filippatos G, Agarwal R, et al. ; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-63.
11. Agarwal R, Filippatos G, Pitt B, et al. ; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84.
12. Rossing P, Anker SD, Filippatos G, et al. ; FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care. 2022;45:2991-8.
13. Heerspink HJL, Collier WH, Chaudhari J, et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med. 2026;32:281-7.
14. Agarwal R, Tu W, Farjat AE, et al. ; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes : a mediation analysis. Ann Intern Med. 2023;176:1606-16.
15. Wheeler DC, Pantalone KM, Guo L, et al. Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study. Clin Kidney J. 2025;18:sfaf305.
16. Mottl A, Scott C, Green JB, et al. ; CONFIDENCE Trial Investigators. Baseline kidney function, albuminuria, and urine albumin-creatinine ratio reduction with finerenone, empagliflozin, or both: post hoc analyses of CONFIDENCE trial. J Am Soc Nephrol. 2026;37:764-76.
17. Perkovic V, Tuttle KR, Rossing P, et al. ; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-21.
